Lerivon

Mianserin Hydrochloride, the active ingredient in Lerivon, is a tetracyclic antidepressant presented as a tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep, and overall functioning, and may be considered when other antidepressants have been ineffective.

GNH USA supplies Lerivon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin Hydrochloride is used in the management of depressive and related disorders.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes. - Anxiety disorders: reduces anxiety symptoms associated with depressive states. - Insomnia related to depression: promotes sleep through its antihistaminic effect.

Mianserin Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to discomfort. - Weight gain: increase in body weight over time. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Blood dyscrasias: neutropenia or agranulocytosis. - Seizures: convulsive episodes.

When prescribing Mianserin Hydrochloride, clinicians should consider several precautionary measures. - Assess cardiovascular status: monitor blood pressure and heart rate. - Evaluate hepatic function: adjust use in patients with liver impairment. - Monitor for suicidal ideation: especially during early treatment. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mianserin Hydrochloride can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; discontinue MAOIs at least 14 days before starting. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression. - Antihypertensive agents: additive blood pressure lowering effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Tricyclic antidepressants: increased risk of cardiac effects. - Anticholinergic drugs: may exacerbate dry mouth and constipation.